Contrasting Immunovant (NASDAQ:IMVT) & Northwest Biotherapeutics (OTCMKTS:NWBO)

Immunovant (NASDAQ:IMVT) and Northwest Biotherapeutics (OTCMKTS:NWBO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Valuation and Earnings

This table compares Immunovant and Northwest Biotherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$413.84 million	($2.84)	-9.58
Northwest Biotherapeutics	$1.38 million	326.43	-$83.78 million	($18.26)	-0.02

Northwest Biotherapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Northwest Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Immunovant has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Northwest Biotherapeutics has a beta of -0.86, meaning that its share price is 186% less volatile than the S&P 500.

Insider and Institutional Ownership

47.1% of Immunovant shares are held by institutional investors. Comparatively, 0.0% of Northwest Biotherapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 2.4% of Northwest Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Immunovant and Northwest Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1	3	6	1	2.64
Northwest Biotherapeutics	0	0	0	0	0.00

Immunovant presently has a consensus price target of $30.78, indicating a potential upside of 13.18%. Given Immunovant’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Immunovant is more favorable than Northwest Biotherapeutics.

Profitability

This table compares Immunovant and Northwest Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-81.55%	-73.09%
Northwest Biotherapeutics	-9,580.90%	N/A	-313.92%

Summary

Immunovant beats Northwest Biotherapeutics on 9 of the 14 factors compared between the two stocks.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.